

PTO/SB/08A

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)



Sheet 1 of 8

Attorney Docket No. PHA 4174.4 (3480/3)

## Complete if Known

Application Number	10/734,829
Filing Date	December 12, 2003
Confirmation Number	not yet assigned
First Named Inventor	Brown et al.
Group Art Unit	not yet assigned 1625
Examiner	not yet assigned ZNDavis

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		
lynnd	1	4,146,721	B1	Rainer	03-27-1979
	2	4,822,805	B1	Takasugi et al.	04-18-1989
	3	4,914,121	B1	Sawai et al.	04-03-1990
	4	5,051,518	B1	Murray et al.	09-24-1991
	5	5,134,142	B1	Matsuo et al.	07-28-1992
	6	5,338,749	B1	Wuest et al.	08-16-1994
	7	5,344,991	B1	Reitz et al.	09-06-1994
	8	5,380,738	B1	Norman et al.	01-10-1995
	9	5,387,592	B1	Bradbury et al.	02-07-1995
	10	5,389,635	B1	Olson	02-14-1995
	11	5,393,790	B1	Reitz et al.	02-28-1995
	12	5,401,765	B1	Lee	03-28-1995
	13	5,418,254	B1	Huang et al.	05-23-1995
	14	5,420,287	B1	Reitz et al.	05-30-1995
lynnd	15	5,434,178	B1	Talley et al.	07-18-1995
lynnd	16	5,466,823	B1	Talley et al.	11-14-1995

Examiner Signature	Lynna N Davis	Date Considered	10/22/2004
--------------------	---------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/734,829
Filing Date	December 12, 2003
Confirmation Number	not yet assigned
First Named Inventor	Brown et al.
Group Art Unit	not yet assigned
Examiner	not yet assigned

Sheet 2 of 8 Attorney Docket No. PHA 4174.4 (3480/3)

<i>17</i>	17	5,475,018	B1	Lee et al.	12-12-1995
	18	5,486,534	B1	Lee et al.	01-23-1996
	19	5,504,215	B1	Talley et al.	04-02-1996
	20	5,508,426	B1	Talley et al.	04-16-1996
	21	5,510,496	B1	Talley et al.	04-23-1996
	22	5,516,907	B1	Talley et al.	05-14-1996
	23	5,521,193	B1	Flynn et al.	05-28-1996
	24	5,521,207	B1	Graneto	05-28-1996
	25	5,534,521	B1	Flynn et al.	07-09-1996
	26	5,565,482	B1	Talley et al.	10-15-1996
	27	5,576,339	B1	Huang et al.	11-19-1996
	28	5,596,008	B1	Lee	01-21-1997
	29	5,616,601	B1	Khanna et al.	04-01-1997
	30	5,639,777	B1	Lee	06-17-1997
	31	5,663,180	B1	Reitz et al.	09-02-1997
	32	5,668,161	B1	Talley et al.	09-16-1997
	33	5,670,510	B1	Huang et al.	09-23-1997
	34	5,672,626	B1	Huang et al.	09-30-1997
	35	5,672,627	B1	Huang et al.	09-30-1997
<i>36</i>	36	5,719,163	B1	Norman et al.	02-17-1998

Examiner Signature	<i>Lynne N Davis</i>	Date Considered	<i>10/22/2007</i>
--------------------	----------------------	-----------------	-------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A

**Complete if Known****INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number	10/734,829
Filing Date	December 12, 2003
Confirmation Number	not yet assigned
First Named Inventor	Brown et al.
Group Art Unit	not yet assigned
Examiner	not yet assigned

Sheet 3 of 8 Attorney Docket No. PHA 4174.4 (3480/3)

37	5,736,579	B1	Reitz et al.	04-07-1998
38	5,739,166	B1	Reitz et al.	04-14-1998
39	5,756,529	B1	Isakson et al.	05-26-1998
40	5,760,068	B1	Talley et al.	06-02-1998
41	5,859,036	B1	Sartori et al.	01-12-1999
42	5,859,257	B1	Talley	01-12-1999
43	5,886,016	B1	Talley et al.	03-23-1999
44	5,908,852	B1	Talley et al.	06-01-1999
45	5,916,905	B1	Weier et al.	06-29-1999
46	5,932,598	B1	Talley et al.	08-03-1999
47	5,935,990	B1	Khanna et al.	08-10-1999
48	5,994,381	B1	Haruta et al.	11-30-1999

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>6</sup>
		Office	Number <sup>4</sup>	Kind Code <sup>2</sup> (if known)			
znd	49	EP	26928	A1	CDC Life Sciences Inc.	04-15-1981	
znd	50	EP	197704	A2	GEC Avionics Limited	10-15-1986	
znd	51	EP	372445	B1	The Du Pont Merck Pharmaceutical Company	06-13-1990	

Examiner Signature

Zina Davis

Date Considered

10/22/2009

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/734,829
Filing Date	December 12, 2003
Confirmation Number	not yet assigned
First Named Inventor	Brown et al.
Group Art Unit	not yet assigned
Examiner	not yet assigned

Sheet	4	of	8	Attorney Docket No.	PHA 4174.4 (3480/3)
-------	---	----	---	---------------------	---------------------

52	EP	418845	A1	Fujisawa Pharmaceutical	03-27-1991
53	EP	745596	A1	Japan Tobacco, Inc.	12-04-1996
54	EP	799823	A1	Sankyo Company Limited	10-08-1997
55	EP	1064964	A2	Pfizer Products Inc.	01-03-2001
56	GB	2294879	A	Merck & Co Inc.	05-15-1996
57	JP	1045374	A	Kokusai Shiyaku KK (abstract)	02-17-1989
58	JP	4277724	A	Sumitomo Electric Ind. Ltd. (abstract)	10-02-1992
59	JP	5323522	A	Fuji Photo Film Co Ltd. (abstract)	12-07-1993
60	WO	92/05162	A1	Taiho Pharmaceutical Co., Ltd.	04-02-1992
61	WO	92/19604	A1	Taiho Pharmaceutical Co., Ltd.	11-12-1992
62	WO	93/14082	A1	Smith-Kline Beecham Corporation	07-22-1993
63	WO	94/13635	A1	Merck Frosst Canada Inc.	06-23-1994
64	WO	94/15932	A1	G.D. Searle & Co.	07-21-1994
65	WO	94/20480	A1	Merck Frosst Canada Inc.	09-15-1994
66	WO	94/26731	A1	Merck Frosst Canada Inc.	11-24-1994
67	WO	95/00501	A2	Merck Frosst Canada Inc.	01-05-1995
68	WO	95/30652	A1	G.D. Searle & Co.	11-16-1995
69	WO	95/30656	A1	G.D. Searle & Co.	11-16-1995
70	WO	96/03387	A1	G.D. Searle & Co.	02-08-1996

Examiner Signature	Lorraine N Davis	Date Considered	10/22/2004
--------------------	------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

*Complete if Known*

Application Number	10/734,829
Filing Date	December 12, 2003
Confirmation Number	not yet assigned
First Named Inventor	Brown et al.
Group Art Unit	not yet assigned
Examiner	not yet assigned

Sheet 5 of 8 Attorney Docket No. PHA 4174.4 (3480/3)

71	WO	96/03388	A1	G.D. Searle & Co.	02-08-1996	
72	WO	96/09293	A1	G.D. Searle & Co.	03-28-1996	
73	WO	96/19462	A1	Japan Tobacco Inc. (abstract)	06-27-1996	
74	WO	96/19463	A1	Japan Tobacco Inc. (abstract)	06-27-1996	
75	WO	96/36617	A1	G.D. Searle & Co.	11-21-1996	
76	WO	96/37467	A1	Merck Frosst Canada Inc.	11-28-1996	
77	WO	97/16435	A1	Merck Frosst Canada Inc.	05-09-1997	
78	WO	97/25045	A1	SmithKline Beecham Corporation	07-17-1997	
79	WO	97/25047	A1	SmithKline Beecham Corporation	07-17-1997	
80	WO	97/25048	A1	SmithKline Beecham Corporation	07-17-1997	
81	WO	98/03484	A1	Merck Frosst Canada Inc.	01-29-1998	
82	WO	98/07425	A1	SmithKline Beecham Corporation	02-26-1998	
83	WO	98/11080	A1	Laboratories UPSA	03-19-1998	
84	WO	98/22442	A1	Angelini Richerche S.p.A. Societa Consatile	05-28-1998	
85	WO	98/47890	A1	G.D. Searle & Co.	10-29-1998	
86	WO	99/14205	A1	Almirall Prodesfarma SA	03-25-1999	
87	WO	99/64415	A1	Pfizer Inc.	12-16-1999	

Examiner Signature	Zinn, N Davis	Date Considered	10/22/2004
--------------------	---------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

## Complete if Known

Application Number	10/734,829
Filing Date	December 12, 2003
Confirmation Number	not yet assigned
First Named Inventor	Brown et al.
Group Art Unit	not yet assigned
Examiner	not yet assigned

Sheet 6 of 8 Attorney Docket No. PHA 4174.4 (3480/3)

## OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
<i>ymd</i>	88	AHLUWALIA et al., "Mechanism of the Debromination in Heteocyclization Using $\alpha,\alpha$ -Dibromocarbonyl Compounds as Synthons." <i>Synth. Commun.</i> , 1989, pp. 619-626, Vol. 19, Nos. 3&4.	
<i>ymd</i>	89	BAGETTA et al., "HIV-1 gp120-Induced Apoptosis in the Rat Neocortex Involves Enhanced Expression of Cyclo-Oxygenase Type 2 (Cox-2)." <i>Biochem. Biophys. Res. Commun.</i> , 1998, pp. 819-824, Vol. 244.	
	90	BARNES et al., "Cyclooxygenase-2 Expression in Airway Cells." <i>Lung Biol. Health Dis.</i> , 1998, pp. 111-127, Vol. 114.	
	91	BOSCH et al., "Efficacy and Tolerability of Intramuscular and Oral Meloxicam in Patients with Acute Lumbago: A Comparison with Intramuscular and Oral Piroxicam." <i>Curr. Med. Res. Opin.</i> , 1997, pp 29-38, Vol. 14, No. 1.	
	92	BUCKMAN et al., "Cox-2 Expression in Induced by UVB Exposure in Human Skin: Implications for the development of skin cancer." <i>Carcinogenesis</i> , 1998, pp. 723-729, Vol. 19, No. 5.	
	93	BUSTOS et al., "Modulation of Eicosanoid Metabolism in Endothelial Cells in a Xenograft Model." <i>J. Clin. Invest.</i> , 1997, pp 1150-1158, Vol. 100, No. 5.	
	94	CHU et al., "Synthesis of Sodium androst-5-ene-17-one-3 $\beta$ -methylene sulfonate." <i>Steroids</i> , 1997, pp 543-545, Vol. 62.	
	95	DIKSHIT et al., "Synthesis and biological activity of 2,3- and 3,4-diarylfurans and 2,3,4-triaryl-2,5-dihydrofurans." <i>Indian J. Chem. Sect. B</i> , 1990, pp 954-960, Vol. 29B, No. 10.	
<i>ymd</i>	96	DOROFEEENKO et al., <i>Khim. Farm. Zh.</i> , 1982, pp. 920-921, Vol. 16.	
<i>ymd</i>	97	FAID-ALLAH et al., "Pyrazole Derivatives with Possible Hypoglycemic Activity." <i>Ind. J. Chem., Sect. B</i> , 1988, pp. 245-249, Vol. 27B, No. 3.	

Examiner Signature	<i>Finne N Davis</i>	Date Considered	10/22/2004
--------------------	----------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

## Complete if Known

Application Number	10/734,829
Filing Date	December 12, 2003
Confirmation Number	not yet assigned
First Named Inventor	Brown et al.
Group Art Unit	not yet assigned
Examiner	not yet assigned

Sheet	7	of	8	Attorney Docket No.	PHA 4174.4 (3480/3)
-------	---	----	---	---------------------	---------------------

98	GIERSE et al., "Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase." Biochem J., 1995, pp. 479-484, Vol. 305, Part 2.
99	HARGREAVES et al., "A New and Sensitive Method for Measuring thermal Nociception in Cutaneous Hyperalgesia." Pain, 1988, pp. 77-88, Vol. 32.
100	HIDA et al., "Non-small Cell Lung Cancer Cyclooxygenase Activity and Proliferation are Inhibited by Non-steroidal Antiinflammatory Drugs." Anticancer Res., 1998, pp. 775-782, Vol. 18, No. 1A.
101	HUANG et al., "A Novel One-Pot Conversion of Methyl Sulfones to Sulfonamides." Tetrahedron Letters, 1994, pp. 7201-7204, Vol. 35, No. 39.
102	KAWAMORI et al., "Chemopreventive Activity of Celecoxib, a Specific Cyclooxygenase-2 Inhibitor, against Colon Carcinogenesis." Cancer Res., 1998, pp. 409-412, Vol. 58, No. 3.
103	KHARASCH et al., "Derivatives of Sulfenic Acids. V. 1-Fluorenone Sulfur Compounds." J. Am. Chem. Soc., 1951, pp. 3240-3244, Vol. 73, No. 7.
104	MIYAMOTO et al., "The effect of cyclooxygenase-2 inhibitor on experimental allergic neuritis." Neuro Report, 1998, pp. 2331-2334, Vol. 9, No. 10.
105	MIYAURA et al., "The Palladium-Catalyzed Cross-Coupling Reaction of Phenylboronic Acid with Haloarenes in the Presence of Bases." Synth. Commun., 1981, pp. 513-519, Vol. 11, No. 7.
106	MUKERJEE et al., "Synthesis of Some Formazans and tetrazolium salts as antiviral agents." Acta. Pharma. Jugosl., 1981, pp. 151-158, Vol. 31.
107	NASJLETTI A. "The Role of Eicosanoids in Angiotensin-Dependent Hypertension." Hypertension, 1998, pp. 194-200, Vol. 31, No. 1, Part 2.
108	NOGAWA et al., "Interaction between inducible nitric oxide synthase and cyclooxygenase-2 after cerebral ischemia." Proc. Natl. Acad. Sci., 1998, pp. 10966-10971, Vol. 95, No. 18.
109	REID et al., "Some New $\beta$ -Diketones Containing the Trifluoromethyl Group." J. Amer. Chem. Soc., 1950, pp 2948-2952, Vol. 72, No. 7.

Examiner Signature	Zenia N. Davis	Date Considered	10/22/2004
--------------------	----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

## Complete if Known

Application Number	10/734,829
Filing Date	December 12, 2003
Confirmation Number	not yet assigned
First Named Inventor	Brown et al.
Group Art Unit	not yet assigned
Examiner	not yet assigned

Sheet 8 of 8 Attorney Docket No. PHA 4174.4 (3480/3)

<i>lynne</i>	110	SANDHYA et al., "A light and electron microscopic study of cytoplasmic phospholipase A <sub>2</sub> and cyclooxygenase-2 in the hippocampus after kainate lesions." Brian Res., 1998, pp. 223-231, Vol. 788.	
	111	SHOUP et al., "Cyclooxygenase-2 Inhibitor NS-398 Improves Survival and Restores Leukocyte Counts in Burn Infection." J. Trauma: Inj., Infec., Crit Care, 1998, pp 215-221, Vol. 45, No. 2.	
	112	SINGER et al., "Cyclooxygenase 2 Is Induced in Colonic Epithelial Cells in Inflammatory Bowel Disease." Gastroenterology, 1998, pp. 297-306, Vol. 115, No. 2.	
	113	SPEIR et al., "Aspirin Attenuates Cytomegalovirus Infectivity and Gene Expression Mediated by Cyclooxygenase-2 in Coronary Artery Smooth Muscle Cells." Circ. Res., 1998, pp. 210-216, Vol. 83, No. 2.	
	114	SUBBARAMAIAH et al., "Inhibition of Cyclooxygenase: A Novel Approach to Cancer Prevention (44170)." Proc. Soc. Exp. Biol. Med., 1997, pp. 201-210, Vol. 216, No. 2.	
	115	TSUJII et al., "Cyclooxygenase Regulates Angiogenesis Induced by Colon Cancer Cells." Cell, 1998, pp. 705-716, Vol. 93, No. 5.	
	116	VLEESCHAUWER et al., "Remarkably Mild and Simple Preparations of Sulfonates, Sulfonyl Chlorides and Sulfonamides from Thioanisoles." Syn. Lett., 1997, pp. 375-377, Vol. 4.	
<i>lynne</i>	117	WILSON et al., "Increased Expression of Inducible Nitric Oxide Synthase and Cyclooxygenase-2 in Barrett's Esophagus and Associated Adenocarcinomas." Cancer Res., 1998, pp. 2929-2934, Vol. 58, No. 14.	
<i>lynne</i>	118	WINTER et al., "Carrageenin-Induced Edema in Hind Paw of the Rat as an Assay for Antiinflammatory Drugs." Proc. Soc. Exp. Biol. Med., 1962. pp. 544-547, Vol. 111.	

Examiner Signature	<i>Zenia N Davis</i>	Date Considered	<i>10/22/2004</i>
--------------------	----------------------	-----------------	-------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.